Cashu
Kura Oncology Reports Strong Q4 Earnings and Progress in Drug Development Strategy
25 days ago
Stocks
Health Care
kura
Kura Oncology
NASDAQ: KURA
+0.18 (0.00%)
8.31
USD
At close at Apr 02, 13:26 UTC
Overview
Loading chart...
Key Stats
Market Cap
725.73M
Dividend Yield
0.00%
P/E Ratio
-2.60
EPS
-2.03
Revenue
53.88M
Avg. Volume
1.47M
About
What does KURA do?
Kura Oncology, headquartered in San Diego, focuses on developing precision medicines for cancer treatment, including small molecule candidates Ziftomenib, Tipifarnib, and KO-2806. The company went public in November 2015 and employs 142 staff.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.